Dianthus Therapeutics (DNTH) Receivables (2022 - 2025)
Historic Receivables for Dianthus Therapeutics (DNTH) over the last 4 years, with Q3 2025 value amounting to $5.0 million.
- Dianthus Therapeutics' Receivables rose 8587.36% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 8587.36%. This contributed to the annual value of $807000.0 for FY2024, which is 6336.03% up from last year.
- As of Q3 2025, Dianthus Therapeutics' Receivables stood at $5.0 million, which was up 8587.36% from $39000.0 recorded in Q2 2025.
- Dianthus Therapeutics' Receivables' 5-year high stood at $5.6 million during Q4 2022, with a 5-year trough of $39000.0 in Q2 2025.
- Over the past 4 years, Dianthus Therapeutics' median Receivables value was $917500.0 (recorded in 2024), while the average stood at $1.9 million.
- Its Receivables has fluctuated over the past 5 years, first soared by 25818.91% in 2024, then plummeted by 9762.2% in 2025.
- Dianthus Therapeutics' Receivables (Quarter) stood at $5.6 million in 2022, then tumbled by 91.18% to $494000.0 in 2023, then skyrocketed by 63.36% to $807000.0 in 2024, then surged by 519.58% to $5.0 million in 2025.
- Its Receivables stands at $5.0 million for Q3 2025, versus $39000.0 for Q2 2025 and $1.0 million for Q1 2025.